Stock Events

Stock Events

EyePoint 

€0.3060
50
-€0.03-7.83%Friday 16:30

Statistics

Day High
0.334
Day Low
0.322
52W High
0.37
52W Low
0.306
Volume
-
Avg. Volume
-
Mkt Cap
26.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q2 2026
Next
-0.95
-0.91
-0.87
-0.83
Expected EPS
-0.82810105936
Actual EPS
N/A

Financials

-704.78%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
28.48MRevenue
-200.7MNet Income

Analyst Ratings

$14.09Average Price Target
The highest estimate is ⁦41.73⁩.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
36%
Hold
55%
Sell
9%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PV3B.XETRA. It's not an investment recommendation.
NVIDIA
12
NVDA
AMD
7
AMD
Apple
6
AAPL
Lilly(Eli) &
6
LLY

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes in the ophthalmology space with treatments for eye diseases, directly competing with EyePoint's eye disease products.
Novartis
NVSEF
Mkt Cap293.18B
Novartis AG, through its acquisition of Alcon, offers a range of eye care products, including pharmaceuticals for chronic eye diseases, competing in the same market as EyePoint.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie, after acquiring Allergan, has a strong presence in the eye care market, especially with products treating eye conditions like dry eye, directly competing with EyePoint's portfolio.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, with its ophthalmology division, develops treatments for eye diseases such as macular degeneration, competing with EyePoint's disease-targeting treatments.
Bausch Health Companies
BHC
Mkt Cap3.07B
Bausch Health Companies, through its eye health division, offers products for various eye conditions, competing in the same space as EyePoint Pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its Vision Care division, provides products for eye health, including pharmaceuticals, competing with EyePoint's offerings.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has a portfolio of ophthalmology drugs treating conditions like glaucoma, directly competing with EyePoint Pharmaceuticals in the eye care market.
Biogen
BIIB
Mkt Cap37.49B
Biogen Inc. has ventured into ophthalmology with treatments for eye diseases, representing a competitive presence in the market for EyePoint Pharmaceuticals.

About

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Show More
CEO
Jay S. Duker
Employees
214
Country
United States
ISIN
US30233G2093
WKN
000A2QJRU

Listings

STU
DE
PV3B.STU
MU
DE
PV3B.MU
XNAS
US
EYPT
F
DE
PV3B.F

0 Comments

Share your thoughts

FAQs

What is EyePoint stock price today?▼
The current price of PV3B.XETRA is €0.31 EUR — it has decreased by -7.83% in the past 24 hours. Watch EyePoint stock price performance more closely on the chart.
What is EyePoint stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange EyePoint stocks are traded under the ticker PV3B.XETRA.
What is EyePoint market cap?▼
Today EyePoint has the market capitalization of 26.38M
When is the next EyePoint earnings date?▼
EyePoint is going to release the next earnings report on March 4, 2027.
What is EyePoint revenue for the last year?▼
EyePoint revenue for the last year amounts to 28.48M EUR.
What is EyePoint net income for the last year?▼
PV3B.XETRA net income for the last year is -200.7M EUR.
How many employees does EyePoint have?▼
As of November 8, 2026, the company has 214 employees.
In which sector is EyePoint located?▼
EyePoint operates in the Health & Wellness sector.
When did EyePoint complete a stock split?▼
The last stock split for EyePoint was on December 9, 2020 with a ratio of 1:10.
Where is EyePoint headquartered?▼
EyePoint is headquartered in WATERTOWN, United States.